Délivrance française de notre brevet d’invention (WO2018/073549) sur de nouvelles compositions antivirales pour le traitement des infections liées aux coronavirus.

L’invention concerne le repositionnement de molécules pour de nouvelles indications antivirales prophylactiques et thérapeutiques contre le coronavirus MERS-CoV (Middle East Respiratory Syndrome-related Coronavirus) chez l’homme et chez les animaux. Signia Therapeutics possède les droits internationaux exclusifs pour ce brevet d’invention.

Our last collaborative study with on Combinations of Baloxavir acid and other inhibitors against seasonal influenza A viruses has been published in Viruses.

Antivirals are recommended for the treatment and control of epidemics and pandemics influenza viruses, especially in high risk populations. Therapeutic combinations constitute an alternative to prevent resistance andreduce antiviral doses. In this way, in collaboration with the Research Centre in Infectious Diseases of CHU Québec and Laval University, we assessed the inhibitory effects of Baloxavir with three NAIs (oseltamivir, zanamivir and peramivir) or two other polymerase inhibitors (favipiravir and ribavirin) in cell culture and in predictive human airway epithelia (HAE) models of infection with influenza A(H1N1)pdm09 and A(H3N2) viruses. Our results suggest that Baloxavir stands as a potential good candidate for combination therapy with several existing drugs to improve antiviral activity and eventually delay drug resistance of influenza type A viruses. Combination therapies with Baloxavir should be further considered for animal studies and clinical investigations.